Actively Recruiting
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
Led by CivaTech Oncology · Updated on 2025-04-04
40
Participants Needed
1
Research Sites
455 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.
CONDITIONS
Official Title
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Suspected or confirmed non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung
- Lung nodule suspicious for NSCLC
- Tumor mass 7 cm or less in maximum diameter by CT scan of chest and upper abdomen
- Clinical stage I or clinical stage II lung cancer
- Not pregnant or nursing
- Negative pregnancy test in premenopausal women
- Use of effective contraception if fertile
- More than 5 years since prior invasive malignancy unless non-melanoma skin cancer or in-situ cancer
You will not qualify if you...
- None specified
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here